Below is a list of the top companies exploring cell therapy treatments for diabetes. [Read more…]
Exploring Advanced Therapies in Diabetes Treatment: A Glimpse into the Future
Diabetes is a chronic condition affecting millions globally, characterized by high blood sugar levels due to the body’s inability to produce or effectively use insulin. Traditional management strategies, including lifestyle modifications and medications, have been vital in controlling diabetes, but they often fall short of addressing the disease’s complexities and long-term complications. In recent years, advanced therapies have emerged, offering new hope for patients.
These therapies encompass innovations such as regenerative medicine, advanced insulin delivery systems, and gene editing technologies, each bringing us closer to more effective and personalized treatments. [Read more…]
The Emerging Role of Regenerative Treatments in Diabetic Wound Care
Diabetes is a condition that affects millions worldwide, and one of its most challenging complications is the development of chronic wounds, including skin wounds and ulcers. These persistent wounds are not only painful and debilitating but also pose significant risks for infection and amputation. Traditional treatments often fall short, leading to the exploration of advanced regenerative therapies, including stem cells and exosomes, which have the potential to transform the management of these difficult conditions.
Companies are making significant strides in this field, and clinical trials are underway to test the effectiveness of these innovative approaches. [Read more…]
U.S. FDA Approves World’s First Cell Therapy (Lantidra) for Type 1 Diabetes
A historic milestone was set on June 28, 2023, when the U.S. Food and Drug Administration (FDA) granted approval for Lantidra to CellTrans, Inc., a company headquartered in Chicago, Illinois. Lantidra is a groundbreaking allogeneic pancreatic islet cellular therapy derived from the pancreatic cells of deceased donors. This landmark decision made it the world’s first cellular therapeutic to be approved for the treatment of type 1 diabetes, a disease that does not yet have a permanent treatment option. Lantridra is designed specifically for adults who have difficulty achieving target glycated hemoglobin levels due to recurring episodes of severe hypoglycemia. [Read more…]
Sernova Advances Cell Pouch Type I Diabetes Trial; Will Test iPSC-Derived Clusters Next
-
Current Trial (Cohorts A–C): Sernova’s current cohorts are focused on testing the safety and tolerability of transplanting donor islets (from cadaveric pancreases) into Sernova’s Cell Pouch device in T1D patients.
-
Future Direction (Post-Cohort C): Next, Sernova plans to launch a new clinical trial using iPSC-derived islet-like clusters, instead of relying on donor islets. This will be in collaboration with Evotec, a leading iPSC company.
-
Why iPSCs Matter: iPSC-derived islet-like clusters offer a renewable, potentially unlimited cell source for treating T1D, overcoming the limitations of donor availability. This aligns with Sernova’s goal of developing a scalable and widely accessible solution.